TriGemX Bio

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
TRPM8
Migraine

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
February 2027 (1)
ElismetrepPhase 3Migraine
Est. primary completion 2027-02 · NCT07645924 · CT.gov ↗
What to watch
October 2027 (1)
ElismetrepPhase 3Migraine
Est. primary completion 2027-10 · NCT07816367 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
ElismetrepPhase 3Acute Migraine
Est. primary completion 2028-06 · NCT07674654 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.